Eli Lilly and Company (NYSE:LLY) Holdings Increased by Forte Capital LLC ADV

Forte Capital LLC ADV lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,640 shares of the company’s stock after acquiring an additional 108 shares during the quarter. Forte Capital LLC ADV’s holdings in Eli Lilly and Company were worth $956,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Simon Quick Advisors LLC raised its holdings in shares of Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $363,000. Terril Brothers Inc. lifted its position in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares in the last quarter. Hartline Investment Corp boosted its stake in shares of Eli Lilly and Company by 1.1% during the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after buying an additional 248 shares during the period. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Eli Lilly and Company by 5.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock valued at $206,683,000 after acquiring an additional 17,461 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Trading Down 2.8 %

Eli Lilly and Company stock traded down $20.94 during mid-day trading on Friday, hitting $734.97. 4,595,138 shares of the company’s stock were exchanged, compared to its average volume of 2,629,045. The company’s 50 day simple moving average is $761.06 and its 200-day simple moving average is $671.38. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a PEG ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the firm posted $1.62 earnings per share. Eli Lilly and Company’s revenue was up 26.0% compared to the same quarter last year. On average, equities analysts anticipate that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.